首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome
【24h】

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

机译:脑脊液sCD19水平对中枢神经系统淋巴瘤的检测及其对疾病预后的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Flow cytometry (FCM) ismore sensitive than conventional cytology for detection of occult leptomeningeal lymphoma; however, some FCM-negative patients show central nervous system (CNS) recurrence. Here, we evaluated the cerebrospinal fluid (CSF) levels of 13 B-cell-associated markers and their contribution to the diagnosis of CNS lymphoma in 91 diffuse large B-cell lymphomas (DLBCL) and 22 Burkitt lymphomas (BLs). From all markers tested, CD19 wasthe most informative. Thus, higher soluble CD19 (sCD19) levels were associated with a greater frequency of neurological symptoms in DLBCL and BL and with parenchymal CNS lymphoma in DLBCL; sCD19 emerged as a powerful predictor of event-free and overall survival in DLBCL and BL, particularly when combined with FCM detection of CNS disease. These results support the utility of combined FCM detection of lymphoma cells and assessment of sCD19 levels in CSF, for more accurate identification of CNS disease in DLBCL and BL patients.
机译:流式细胞术(FCM)比传统的细胞学检测潜伏性脑膜脑淋巴瘤更为敏感。但是,一些FCM阴性患者显示中枢神经系统(CNS)复发。在这里,我们评估了13种B细胞相关标记的脑脊液(CSF)水平及其对91例弥漫性大B细胞淋巴瘤(DLBCL)和22例Burkitt淋巴瘤(BLs)对CNS淋巴瘤的诊断的贡献。在所有测试的标记中,CD19是信息最丰富的。因此,较高的可溶性CD19(sCD19)水平与DLBCL和BL中神经症状的发生频率较高以及DLBCL中的实质性中枢神经系统淋巴瘤相关。 sCD19成为DLBCL和BL患者无事件生存和总体生存的有力预测指标,尤其是与FCM检测中枢神经系统疾病相结合时。这些结果支持联合FCM检测淋巴瘤细胞和评估CSF中sCD19水平的实用性,以更准确地鉴定DLBCL和BL患者的CNS疾病。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号